The Development of Plasma Amyloid-β Assay and its Significance in Alzheimer’s Disease
contributed by Shimadzu |
The combination of immunoprecipitation (IP) with MALDI-TOF MS resulted in IP-MALDI-MS, an analytical technique that led to the first successful detection of plasma amyloid-β (Aβ) by mass spectrometry. This helped to identify plasma APP669–711/Aβ1–42 ratio, a novel biomarker that correlates with amyloid PET. Samples from Japan and Australia revealed a high degree of concordance between amyloid PET and plasma APP669–711/Aβ1–42 ratio, plasma Aβ1–40/Aβ1–42 ratio, and a combination of both. With advances in disease-modifying drugs, blood-based biomarkers increase in value due to their role in screening subjects and drug effects, and as adjuncts in the diagnosis of AD.
Log in or register to gain full unlimited access to all content on the The Pathologist site. It’s FREE!